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Background: The Danish Myelodysplastic Syndromes Database (DMDSD) comprises 
nearly all patients diagnosed with myelodysplastic syndromes (MDS) in Denmark since 
2010. The DMDSD has not yet been used for epidemiological research and the quality of 
registered variables remains to be investigated.
Objective: To describe characteristics of the patients registered in the DMDSD and to 
calculate predictive values and the proportion of missing values of registered data records.
Methods: We performed a nationwide cross-sectional validation study of recorded disease 
and treatment data on MDS patients during 2010–2019. Patient characteristics and the 
proportion of missing values were tabulated. A random sample of 12% was drawn to 
calculate predictive values with 95% confidence intervals (CIs) of 48 variables using 
information from medical records as a reference standard.
Results: Overall, 2284 patients were identified (median age: 76 years, men 62%). Of these, 
10% had therapy-related MDS, and 6% had an antecedent hematological disease. 
Hemoglobin level was less than 6.2 mmol/L for 59% of patients. Within the first two 
years of treatment, 59% received transfusions, 35% received erythropoiesis-stimulating 
agents, and 15% were treated with a hypomethylating agent. For the majority of variables 
(around 80%), there were no missing data. A total of 260 medical records were available for 
validation. The positive predictive value of the MDS diagnosis was 92% (95% CI: 88–95). 
Predictive values ranged from 64% to 100% and exceeded 90% for 36 out of 48 variables. 
Stratification by year of diagnosis suggested that the positive predictive value of the MDS 
diagnosis improved from 88% before 2015 to 95% after.
Conclusion: In this study, there was a high accuracy of recorded data and a low proportion 
of missing data. Thus, the DMDSD serves as a valuable data source for future epidemiolo-
gical studies on MDS.
Keywords: myelodysplastic syndromes, cohort, validation, accuracy, database
Introduction
Myelodysplastic syndromes (MDS) encompasses a heterogeneous group of myeloid 
neoplasms characterized by inefficient hematopoiesis, morphologic dysplasia, and vari-
able degrees of cytopenias.1,2 MDS can be indolent or rapidly progressive, and may 
transform into secondary acute myeloid leukemia (sAML).1,2 The annual age-adjusted 
incidence is approximately 4 per 100,000 persons, increasing markedly with advancing 
age.3–5 Despite improvements in treatment and increasingly use of allogeneic bone 
marrow transplantation (allo-HSCT), the five-year overall survival remains around 30%.5
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Denmark is known worldwide for its many high quality 
population-based health-care registries.6 The Danish 
Myelodysplastic Syndromes Database (DMDSD) was 
launched in 2010 as a nationwide population-based data-
base, currently covering at least 98% of all Danish MDS 
patients.7 It contains detailed clinical data on MDS sub-
types, comorbidity, laboratory records, cytogenetic altera-
tions, treatment and progression to acute myeloid leukemia 
(sAML). Through linkage to the extensive network of 
Danish health-care registries, the DMDSD holds several 
epidemiological research possibilities. The use of data may 
add to the understanding of the epidemiology of MDS, 
including time trends in incidence and survival, clinical 
course, and effectiveness and safety of different treatment 
modalities.
Given that validation of a data source is a prerequisite 
prior to its use in epidemiological research, the objective 
of this study was to describe patient characteristics, the 
proportion of missing values, and the validity of data 
records in the DMDSD.
Methods
Setting
The Danish health-care system is universal and tax- 
supported, providing free of charge and equal access to 
primary and hospital care for all Danish citizens.6 Patients 
with MDS are treated with chemotherapy at six specialized 
hematological departments in Denmark and four hemato-
logical departments treat MDS patients with best suppor-
tive care (transfusions, growth-factors, and antibiotics). 
Two hospital departments are accredited to perform allo- 
HSCT. Cytogenetic and mutational analyses are performed 
at three laboratories in Denmark and karyotypes are docu-
mented according to the International System for Human 
Cytogenetic Nomenclature (ISCN).8
The Danish Myelodysplastic Syndrome 
Database
The DMDSD was founded by the Danish Society of 
Hematology as a nationwide clinical quality database 
with prospectively collected data on patients with incident 
MDS starting from January 2010. The main aim of the 
DMDSD is to register all cases of MDS, including base-
line characteristics, and treatment information to ensure 
comparable diagnostic work-up and treatment of MDS in 
Denmark. The database can also be used for research 
purposes.9
Data are submitted to the DMDSD through an online 
registration system. Up to five standardized registration 
forms are used to collect data for the DMDSD (Table 
1). The first form is completed at diagnosis. The second 
and third forms are completed two and five years after 
diagnosis or earlier in case of progression to sAML, death, 
or termination of outpatient follow-up. A follow-up form 
is completed at death or termination of outpatient follow- 
up. The result of the cytogenetic evaluation is currently 
reported according to the Revised International Prognostic 
Scoring System (IPSS-R) by a clinical cytogeneticist at 
a separate registration form at diagnosis. Prior cytogenetic 
results reported according to the International Prognostic 
Scoring System (IPSS) were revised and updated accord-
ing to IPSS-R by clinical cytogeneticists in 2020. IPSS-R 
data are, however, currently not available to researchers, 
and therefore they are not validated in this study, but IPSS 
characteristics are shown in Table 2.
Two Danish health-care registries are of central impor-
tance to the DMDSD. The Civil Registration System pro-
vides data about vital status, date of death, and residential 
area.10 The Danish National Patient Registry (DNPR) pro-
vides data on primary and secondary discharge diagnoses 
(eg MDS ICD-10 codes) from all Danish hospitals since 
1977.11 Complete and valid linkage between these regis-
tries and the DMDSD is done via the unique central 
personal registry number assigned to all Danish citizens.10
To ensure that the DMDSD captures all newly diag-
nosed MDS patients, lists of patients with a newly regis-
tered MDS ICD-10 code according to the DNPR are 
provided for all hematological departments to confirm 
the diagnosis. If the diagnosis is correct, the patient is 
recorded in the DMDSD and the registration form at 
diagnosis is completed. To ensure inclusion of incident 
MDS patients only, a look back period to 2001 is applied. 
Reminders to fill out the registration forms including 
2-year data, 5-year data, follow-up-data and cytogenetic 
details, are also sent to the clinical departments. It is 
mandatory for all clinical departments to register MDS 
patients in the DMDSD and according to Danish law 
patient consent is not required.
Patient Population and Study Design
We performed a nationwide cross-sectional validation 
study. We identified all patients with a diagnosis of MDS 
registered in the DMDSD from January 1st 2010 until 
October 1st 2019. Then, a random validation sample of 
12% of all patients diagnosed with MDS over a 10-year 
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Table 1 Data Recorded on Five Registration Forms Used by the Danish Myelodysplastic Syndromes Database
Registration Form and Time of Registration Variables
At diagnosis Name, civil registration number, and demographic data
To be filled out at diagnosis Diagnosis according to WHO(2008/2016)/ICD-10
Date of diagnosis
Prior hematological disease, prior chemotherapy or prior radiotherapy (yes/no/unknown)
Results of cytogenetic evaluation (grouped according to IPSS-R)
Cytopenia
Anemia (< 6.2 mmol/l (yes/no)**
Thrombocytopenia (< 100 x109/L) (yes/no)**
Neutropenia (< 1.8 x109/L) (yes/no)**
Blast percentage in blood and bone marrow
Treatment with blood transfusion prior to diagnosis (yes/no/unknown)
Presence of material in biobank (yes/no/unknown)
Laboratory records*
Cytogenetic registration form Date of diagnostic bone marrow sample
To be filled out at diagnosis by a clinical Diagnoses according to WHO (2008/2016)/ICD-10
Cytogeneticist Cytogenetic result (normal, clonal changes, not done, no mitoses)
Cytogenetic material (peripheral blood, bone marrow, others)
Number of analyzed metaphases, abnormal metaphases and clonal changes
ISCN karyotype
IPSS-R
2-year data and 5-year data Diagnosis according to WHO (2008/2016)/ICD-10
Registration form to be filled out two and five Date of follow-up
Years after diagnosis or in case of progression to Treatment
AML, death or termination of outpatient follow- Transfusion (yes/no)**
Up Erythropoiesis-stimulating agents (yes/no)**
Granulocyt-colony-stimulating-factors (yes/no)**
Iron chelating agents (yes/no)**
Hydroxyurea (yes/no)**






Progression to acute myeloid leukemia (yes/no). If yes, date of progression
Participation in protocol (yes/no)
Bone marrow transplantation (yes/no). If yes, date and type
Follow up form Status (dead/alive)
At death or termination of follow-up as an Date of death or end of follow-up
Out-patient Did the patient die at the hospital (yes/no)
Was follow-up terminated from the department (yes/no)
Referred to follow-up at another department (yes/no)
Notes: *Middle cell volume, hemoglobin, platelet count, white blood cell count, monocyte count, lactate dehydrogenase, ferritin, urate, erythropoietin, CD 34 positive cells, 
myoblasts, packed cell volume. **In order to register a “yes” you have to tick a “box”. If nothing is ticked off a “no” is automatically registered. 
Abbreviations: AML, acute myeloid leukemia; ICD, International Classification of Diseases; ISCN, International System for Human Cytogenetic Nomenclature; IPSS-R, 
International Prognostic Scoring System; WHO, World Health Organization.
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period was drawn. This number was chosen to ensure that 
we included a sample size of at least 10% of the whole 
MDS population, as we expected that some of the medical 
records could not be retrieved.
Record Review
For validation, we selected 48 variables from the DMDSD 
(18 from the registration form at diagnosis and 15 from 
each of the registration forms including 2-year data and 
5-year-data), which we regarded most important for study-
ing MDS (Table 2). These were validated using informa-
tion from medical records, the Danish Pathology Databank 
(Patobank), and the clinical laboratory information system 
as the gold standard.12 Patobank is a nationwide database 
that contains descriptions of pathology examinations since 
1997.13 It is accessible online at all Danish hospitals. 
Accepted values and gold standards for the 48 variables 
are shown in Table 2. For example, laboratory values were 
accepted from blood samples conducted ± 30 days from 
date of diagnostic bone marrow examination and correct 
date of progression to AML was accepted with a range of 
± 7 days. Data on vital status and date of death were not 
validated in this study, as this information is routinely 
drawn from the Civil Registration System and linked to 
Table 2 Accepted Values and Gold Standards for the Validation of 48 Variables from the Danish Myelodysplastic Syndromes 
Database*
Variables Correct Specification of Registered Variables Gold Standards
Diagnosis MDS unclassified or specification of MDS subtype Patobank/Medical records
Date of diagnosis Date of diagnostic bone marrow sample (± 14 days) Patobank
Prior hematological disease (>3months) Yes/no/unknown Medical records
Prior chemotherapy Yes/no/unknown Medical records
Prior radiotherapy Yes/no/unknown Medical records
Anemia (< 6.2 mmol/L) Yes/no ** Laboratory information system
Thrombocytopenia (<100 x 109/L) Yes/no ** Laboratory information system
Neutropenia (<1.8 x109/L) Yes/no ** Laboratory information system
Blast percentage in bone marrow Exact value Patobank/Medical records
Blood transfusion prior to diagnosis Yes/no/unknown Medical records
MCV (fL) *** Laboratory information system
Hemoglobin (mmol/L) *** Laboratory information system
Platelet count (109/L) *** Laboratory information system
White blood cell count (109/L) *** Laboratory information system
Leucocyte count (109/L) *** Laboratory information system
Monocyte count (109/L) *** Laboratory information system
Lactate dehydrogenase (U/L) *** Laboratory information system
Ferritin (µg/L) *** Laboratory information system
Transfusion Yes/no** Medical records
Erythropoiesis-stimulating agents Yes/no** Medical records
G-CSF Yes/no** Medical records
Iron-chelating agents Yes/no** Medical records
Hypomethylating agents Yes/no** Medical records
Hydroxurea Yes/no** Medical records
AML-like chemotherapy Yes/no** Medical records
Immunosuppresive agents Yes/no** Medical records
Lenalidomide Yes/no** Medical records
Protocol participation Yes/no/unknown Medical records
Progression to sAML Yes/no/unknown Patobank/medical records
Date of progression to sAML Date specified (± 7 days) Patobank/medical records
Bone marrow transplantation Yes/no Medical records
Date of bone marrow transplantation Exact date of transplantation Medical records
Type of bone marrow transplantation Myeloablative/reduced intensity conditioning or autologous Medical records
Notes: *Variables regarding treatment, progression to sAML, protocol participation and bone marrow transplantation were validated twice (at a registration form including 
2-year data and 5-year data respectively, accounting for 30 variables in total). **In order to register a “yes” you have to tick a “box”. If nothing is ticked off a “no” is 
automatically registered. ***Exact value measured on day of diagnostic bone marrow sample (±30 days). 
Abbreviations: G-CSF, granulocyte-colony-stimulating-factors; MCV, middle cell volume; sAML, secondary acute myeloid leukemia.
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the DMDSD. During the validation process, one of four 
outcomes were recorded: 1) consistent with reference stan-
dard, 2) not consistent with reference standard, 3) missing 
value (when information was present in reference, but not 
in the DMDSD, and 4) not relevant (eg type of allo-HSCT, 
when the patient was not transplanted).
Validation was performed during March through 
August 2020. All patients were confirmed to have MDS 
by assessment of the morphological bone-marrow descrip-
tions in Patobank, assessment of cytopenias, evaluation of 
chromosomal aberrations, and mutational markers accord-
ing to “The World Health Organizations classification of 
myeloid neoplasms ICD-10 2008/2016”.2 All medical 
records were reviewed by one specialist registrar in hema-
tology (TBL), and any questions about interpretation of 
data were discussed with two consultants in hematology 
specialized in MDS (JMN and LSGØ).
Statistical Analysis
Descriptive characteristics for the total MDS population 
and the validation sample (with and without a MDS diag-
nosis) including the proportion of missing data were tabu-
lated. Continuous variables were reported as medians with 
25th and 75th percentiles. Patients for whom we were 
unable to retrieve information from medical records or 
who did not fulfill the diagnostic criteria for a MDS- 
diagnosis were excluded from the study. Predictive values 
were calculated as the number of patients with correct 
registration divided by the number of patients registered. 
Predictive values for categorical variables were computed 
within strata of “yes”, “no”, and overall. If one or more 
variables from a patient could not be evaluated because of 
missing information in the reference (eg no laboratory 
measurements available), the patient was not included 
when calculating predictive values for that specific vari-
able. Further, we examined if the predictive values varied 
according to subgroup of patients defined by departments 
(university hospitals vs regional hospitals) and date of 
diagnosis (before and after 2014). Estimates were given 
with binomial 95% confidence intervals (CIs). To clarify 
whether incorrect registration was represented by few 
patients or equally distributed among all patients, we cal-
culated a median sum score of correctly coded variables 
within the registration form filled out at diagnosis (18 
variables).
In addition, the annual incidence rate for MDS was 
computed as the number of incident MDS patients regis-
tered in the DMDSD from 2014–2018 divided by the 
Danish midyear population in 2014–2018 (per 
100.000).14 A CI around the estimate was calculated with 
a Poisson approximation. Data were entered into a Redcap 
database15,16 and Stata version 16 was used for the sam-
pling process and the statistical analyses.
The study was approved by the Danish Data Protection 
Agency (record number: 1–16-02-321-18) and the Danish 
Patient Safety Authority (record number 3–3013- 2960/1). 
According to Danish law, no approval from an ethical 
committee was required.
Results
The overall MDS cohort comprised 2284 individuals. Of 
these, we randomly sampled 272 patients for the validation 
study. We were unable to obtain medical records on 12 
patients and they were excluded. Patient characteristics 
and the proportion of missing values are presented in 
Table 3 for the registration form completed at diagnosis 
and the registration form including 2-year data. The med-
ian age at diagnosis was 76 years with a male predomi-
nance (62%). Of the 2284 patients, 140 (6%) patients had 
an antecedent hematological disease and 222 (10%) 
patients had a history of chemotherapy or radiotherapy 
prior to the diagnosis of MDS (therapy-related MDS). 
The median hemoglobin level was 6.1 mmol/L, the median 
platelet count was 125 x 109/L and the median white blood 
cell count was 1.8 x 109/L. The median blast count in the 
bone marrow was 2%. Karyotype was available for 2020 
patients (88%). Overall characteristics for the validation 
sample were broadly similar to the total MDS population, 
whereas the misclassified MDS patients were older, more 
frequently diagnosed before 2015, more often had the 
WHO subtype “MDS unclassifiable”, and had less pro-
nounced changes in laboratory values (except from white 
blood cell count).
For 15 out of 18 variables on the registration form filled 
out at diagnosis, we observed no missing data. “Blood 
transfusion prior to diagnosis” and “monocyte count” had 
a high proportion of missing values (53% for both). For 13 
out of 18 variables on the registration form filled out at 
diagnosis a possible registration was “unknown”. Ferritin 
had the highest proportion of “unknown” registrations 
(15%) followed by “prior radiotherapy” (8%) and “prior 
chemotherapy” (7%). None of the patients with an 
“unknown” registration for prior radiotherapy or che-
motherapy had, however, received this treatment according 
to information in medical records.
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Table 3 Characteristics of Patients Registered in the Danish Myelodysplastic Syndromes Database. Data are Shown for the Whole 
Population, the Validation Sample and the Misclassified MDS Patients
Total MDS Population Validation Sample Misclassified as MDS Patients
At diagnosis (number of patients) 2284 238 22
Male sex 1417 (62%) 131 (55%) 15 (68%)
Median age, years (IQR) 76 (68–82) 76 (68–82) 78 (63–82)
Enrolment year
2010–2014 1185 (52%) 117(49%) 16 (73%)
2015–2019 1099 (48%) 121 (51%) 6 (27%)
Diagnostic WHO subtype
MDS with single lineage dysplasia 241 (11%) 29 (12%) –
MDS with ringed sideroblasts 238 (10%) 26 (11%) 0
MDS with excess blasts 563 (25%) 57 (24%) 0
MDS with multi-lineage dysplasia 665 (29%) 70 (29%) -
MDS with isolated del(5q) 77 (3%) 11 (4%) 0
MDS unclassifiable 500 (22%) 46 (19%) 16 (72%)
Prior hematological disease (>3 months) 140 (6%) 19 (8%) 0
Missing 0 0 0
Unknown 59 (3%) 6 (2%) 0
Prior chemotherapy 126 (6%) 13 (5%) 0
Missing 0 0 0
Unknown 164 (7%) 14 (6%) 4 (18%)
Prior radiotherapy 96 (4%) 9 (4%) -
Missing 0 0 0
Unknown 175 (8%) 15 (6%) -
Blood transfusion prior to diagnosis 106 (5%) 14 (6%) 0
Missing 1218 (53%) 122 (51%) 15 (68%)
Unknown 128 (6%) 16 (7%) -
IPSS
Good-risk 1013 (44%) 107 (45%) 12 (55%)
Intermediate-risk 746 (33%) 80 (34%) -
Poor-risk 261 (11.5%) 22 (9%) -
Unknown 254 (11%) 29 (12%) -
Missing 10 (0.5%) 0 0
Anemia (hemoglobin < 6.2 mmol/L) 1353 (59%) 135 (56%) 10 (45%)
Thrombocytopenia (platelets < 100 x 109/L) 905 (40%) 83 (35%) 6 (27%)
Neutropenia (WBC < 1.8 x 109/L) 1026 (45%) 97 (41%) 11 (50%)
Blast count marrow, median (IQR) 2 (0–7) 2 (0–5) 1 (0–2)
Missing 0 0 0
Unknown 133 (6%) 6 (2.5%) 4 (18%)
MCV, fL, median (IQR) 99 (91–106) 101 (94–107) 97 (88–103)
Missing 0 0 0
Unknown 130 (6%) 8 (3%) 1 (5%)
(Continued)
https://doi.org/10.2147/CLEP.S306857                                                                                                                                                                                                                                 
DovePress                                                                                                                                                                    
Clinical Epidemiology 2021:13 444
Lauritsen et al                                                                                                                                                        Dovepress




























































Table 3 (Continued). 
Total MDS Population Validation Sample Misclassified as MDS Patients
Hemoglobin, mmol/L, median (IQR) 6.1 (5.5–6.9) 6.2 (5.5–7.0) 7 (5.6–8.2)
Missing 0 0 0
Unknown 11 (0.5%) 0 0
Platelet count, x 109/L, median (IQR) 125 (68–235) 140 (76.0–252) 155 (99–250)
Missing 0 0 0
Unknown 15 (0.6%) 0 0
WBC, x 109/L, median (IQR) 1.8 (0.9–3.5) 2.1 (1.1–3.7) 1.6 (1.1–4.2)
Missing 0 0 0
Unknown 45 (2%) - 0
Leucocyte count, x 109/L, median (IQR) 3.8 (2.5–6.1) 4 (2.4–6.4) 3.9 (6.3)
Missing 0 0 0
Unknown 13 (0.6%) - 0
Monocyte count, x 109/L, median (IQR) 0.3 (0.2–0.6) 0.3 (0.2–0.7) 0.7 (0.2–0.8)
Missing 1218 (53%) 122 (51%) 14 (64%)
Unknown 44 (2%) - 0
LDH, U/L, median (IQR)* 208 (175–252) 205 (171–241) 200 (170–236)
Missing 0 0 0
Unknown 88 (4%) 9 (4%) 0
Ferritin (µg/L) 362 (174–691) 366 (186–698) 168 (79–398)
Missing 0 0 0
Unknown 331 (15%) 26 (11%) 2 (9%)
2- year data (number of patients) 1910 (84%) 197 (83%) 21 (95%)
Treatment
Transfusion 936 (49%) 100 (51%) 5 (24%)
Erythropoiesis-stimulating agents 667 (35%) 73 (37%) 4 (19%)
Granulocyte-colony-stimulating-factors 220 (12%) 22 (11%) –
Hypomethylating agents (Azacitidine) 291 (15%) 25 (13%) 0
Iron-chelating agents 61 (3%) 7 (4%) –
Hydroxyurea 88 (5%) 7 (4%) –
AML-like chemotherapy 106 (6%) 12 (6%) 0
Immune suppressive agents 63 (3%) 9 (5%) 0
Lenalidomide 28 (2%) – 0
Protocol participation 111 (5%) 6 (3%) 0
Missing 374 (16%) 0 0
Unknown 54 (2%) 5 (2%) 0
Progression to sAML 238 (13%) 31 (16%) 0
Missing 55 (3%) 5 (2.5%) 0
Unknown 40 (2%) - –
Date of progression to sAML 139 (58%) 21 (68%) –
Missing 99 (42%) 10 (32%) –
Unknown 0 0 –
Allo-HSCT 109 (5%) 17 (9%) 0
Missing 374 (16%) 0 0
Unknown 0 0 0
(Continued)
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Predictive values for each of the 18 variables reported 
at diagnosis are shown in Figure 1. The positive predic-
tive value of the MDS diagnosis was 91.5% (95% CI: 
87.5–94.7). Of the 22 patients who did not fulfil the 
criteria for MDS, the diagnoses were unsettled cytopenia, 
chronic myelomonocytic leukemia, chronic idiopathic 
neutropenia, reactive anemia, chronic myeloproliferative 
neoplasia, idiopathic thrombocytopenic purpura, and 
cytopenia caused by treatment with cytotoxic drugs. The 
overall predictive values ranged from 86.9% for “blood 
transfusion prior to diagnosis” (95% CI: 78.6–92.8) to 
97.8% (95% CI: 94.8–99.3) for “prior radiotherapy” and 
were higher than 90% for 16 of 18 variables.
Of the 1910 patients with a completed registration form 
including 2-year data, 936 (49%) received treatment with 
transfusion, 667 (35%) received treatment with erythropoi-
esis-stimulating agents, and 291 (15%) received treatment 
with a hypomethylating agent. Progression to sAML 
occurred in 238 (13%) patients and 109 patients (5%) 
were treated with allo-HSCT. Four of 15 variables con-
tained missing data. “Date of progression to AML” had the 
highest proportion of missing data (42%) followed by 
“participation in protocol” (16%) and “allo-HSCT” (16%).
The overall predictive values for variables included in 
the 2-year data registration form ranged from 71.4% (95% 
CI: 47.7–87.3) for “date of progression to AML” to 99.5% 
(95% CI: 97.2–99.9) for “treatment with hydroxyurea” and 
were greater than 94% for 11 out of 15 variables 
(Figure 2). Due to relatively few observations, no solid 
conclusions could be derived from predictive values on 
patients receiving iron-chelating treatment, hydroxyurea, 
AML-like-chemotherapy, immune modulating agents, and 
lenalidomide. The predictive values were, however, 
generally high for patients not receiving the aforemen-
tioned treatment modalities.
The registration form including 5-year data was com-
pleted for 449 patients (20%) and characteristics and pre-
dictive values are shown in Supplemental Table 1 and 
Figure 1.
Stratification by departments (university hospitals vs 
regional hospitals) revealed broadly comparable predictive 
values for the 18 variables from the registration form filled 
out at diagnosis (Supplemental Table 2). The stratified 
analysis suggested, however, that the positive predictive 
value of the MDS diagnosis improved from 87.7% before 
2015 to 95.3% thereafter. The overall median sum score 
for a correctly filled registration form at diagnosis was 16 
(25th-75th: 15–17). The overall incidence of MDS was 
6.0 per 100,000 persons (95% CI: 5.7–6.3).
Discussion
Our study provided patient characteristics of 2284 unse-
lected MDS patients registered in the DMDSD during 
2010–2019. Further, we showed that data in the DMDSD 
were highly valid with a positive predictive value of the 
MDS diagnosis of 91.5% and predictive values exceeding 
90% for the majority of study variables.
Descriptive characteristics, including the age- and sex 
composition, laboratory values, and proportion of therapy- 
related MDS-patients, reported in our study, are broadly 
comparable to findings from the Swedish MDS Registry,17 
the Düsseldorf MDS Registry18 and six cross-sectional 
physician surveys from the United States.19
In the Swedish MDS Registry, approximately 50% of 
the patients from 2009–2013 received transfusions at 
diagnosis.17 In the DMDSD, information on blood 
Table 3 (Continued). 
Total MDS Population Validation Sample Misclassified as MDS Patients
Date of allo-HSCT 109 (100%) 17 (100%) –
Missing 0 0 –
Unknown 0 0 –
Type of allo-HSCT 109 (100%) 17 (100%) –
Missing 0 0 –
Unknown 0 0 –
Notes: *For patients < 70 years old normal range for LDH is 105 to 205 U/L and for patients > 70 years normal range for LDH is 115 to 255 U/L.  - Data not shown due to 
small numbers. 
Abbreviations: allo-HSCT, allogeneic hematopoietic stem cell transplantation; IPSS, International Prognostic Scoring System; IQR, interquartile range (25th to 75th 
percentiles); LDH, lactate dehydrogenase; MCV, middle cell volume; sAML, secondary acute myeloid leukemia; WBC, white blood cell count; WHO, World Health 
Organization.
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Figure 1 Predictive values for 18 variables from the registration form completed at diagnosis from the Danish Myelodysplastic Syndromes Database.  
Notes: *Number of correctly coded records/number of relevant records reviewed (missing/unknown values excluded). 
Abbreviations: BM, bone marrow; CI, confidence interval.
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Figure 2 Predictive values for 15 variables from the registration form including 2-year data from the Danish Myelodysplastic Syndromes Database.  
Notes: *Number of correctly coded records/number of relevant records reviewed (missing/unknown values excluded). 
Abbreviations: Allo-HSCT, allogeneic hematopoietic stem cell transplantation; CI, confidence interval, ESASs, erythropoiesis-stimulating agents; G-CSFs, granulocyte- 
colony-stimulating-factors; sAML, secondary acute myeloid leukemia.
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transfusion prior to diagnosis had a high proportion of 
missing data (53%), and only 5% of the patients were 
registered as transfusion-dependent at diagnosis. 
Conversely, 59% of the patients in the DMDSD had pro-
nounced anemia (less than 6.2 mmol/L) and 49% of the 
patients were treated with transfusion within the first two 
years. This suggests that information about blood transfu-
sion is underreported at the time of diagnosis in the 
DMDSD. However, complete transfusion data, including 
type of product and time of transfusion can be supplemen-
ted with data from the Danish Transfusion Database.20 
Information about date of progression to sAML was also 
missing for a considerably proportion of patients. 
However, this information can easily be retrieved from 
the Danish National Acute Leukemia Registry.21
The overall use of erythropoiesis-stimulating agents, 
granulocyte-colony-stimulating factors, hypomethylating 
agents, and lenalidomide in an unselected MDS- 
population is sparsely reported in prior studies.19,22 
Within the first two years of diagnosis, 35% of patients 
in the DMDSD were treated with an erythropoiesis- 
stimulating agent and only 2% of patients in the 
DMDSD were treated with lenalidomide. This is some-
what lower than in two studies from the United States 
where erythropoiesis-stimulating agents were used in 
50–60% of recently diagnosed MDS patients, while lena-
lidomide was used for around 7% of recently diagnosed 
MDS patients.19,22 The use of granulocyte-colony- 
stimulating-factors (12%) and hypomethylating agents 
(15%) reported in the DMDSD were however in line 
with results from the two aforementioned studies from 
the United States. As such, our study confirms findings 
from the United States; indicating that disease-modifying 
therapies (hypomethylating agents and lenalidomide) 
approved for MDS are used for a minority of MDS 
patients only. Allo-HSCT and clinical trial enrolment 
were only registered for a minority of MDS patients 
(5%) which also is in line with data from the United 
States.19
To the best of our knowledge, no prior validation 
studies of MDS registries have been performed. 
Although direct comparison to our findings therefore can-
not be made, two validation studies of The Danish 
National Acute Leukemia Registry and The Danish 
National Lymphoma Registry showed high completeness 
and accuracy of registered variables.21,23 The positive 
predictive value of an MDS diagnosis in our study 
(91.5%) was lower than the positive predictive value of 
an acute myeloid leukemia diagnosis in the Danish 
National Acute Leukemia Registry [99.6% (95% CI: 
98.1–100)]21 and of a lymphoma subtype diagnosis in 
the Danish National Lymphoma Registry [98.5% (95% 
CI: 97.8–99.1)].24 The misclassified cases in the 
DMDSD reflect the challenges of establishing a correct 
diagnosis of MDS.25,26 Cases in which secondary causes 
of cytopenia are excluded but the karyotype is normal, 
blast-count, and dysplastic changes are few and other 
features convincing for an MDS diagnosis are lacking 
often present diagnostic difficulties. Most of the misclas-
sified patients in the present study, had “idiopathic cyto-
penia of undetermined significance”1 or clonal cytopenia 
of unknown significance.1 Both these conditions are poten-
tial pre-phases of MDS or other hematological malignan-
cies, but can also persist without clinical manifestation or 
progression.27–29 Mutational profiling and flow cytometry 
are used increasingly among patients with MDS and may 
contribute to the diagnosis of MDS. No generally accepted 
minimal criteria or classification using mutational markers 
or flow cytometry are however yet available.30 
Reassuringly, our data suggested that the positive predic-
tive value of the MDS diagnosis has improved over time. 
Furthermore, the positive predictive value is presumably 
higher in the DMDSD if analyses are restricted to inter-
mediate- to high-risk MDS patients as they often have 
more evident changes in the bone marrow, more pro-
nounced cytopenias and more severe cytogenetic altera-
tions which makes the diagnosis more obvious.
The DMDSD has several strengths. It is population- 
based, it contains detailed and valid clinical information 
on more than 2200 MDS patients, and it can be linked with 
other Danish health-care registries.6 The Swedish MDS- 
registry is comparable to the DMDSD regarding registered 
variables but it has a larger sample size.31 The European 
MDS Registry (EUMDS) also contains detailed informa-
tion on patients with MDS of IPSS low and intermediate-1 
subtypes and has recently been extended to enroll all 
subtypes of MDS. Reporting of MDS-patients to the 
EUMDS is however optional, which may cause selection 
bias. The Surveillance, Epidemiology, and End Results 
(SEER) Program contains a large sample size, but has 
numerous limitations including lack of validation of the 
diagnosis, selection bias, and lack of clinical information.4
The DMDSD has important limitations. It lacks 
detailed treatment information, eg start/end date of treat-
ment, evaluation of treatment response according to the 
International Working Group Criteria, performance 
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status, lifestyle factors, family history of myeloid disease 
and comorbidity.32,33 However, data from the DMDSD 
are easily and cost-effectively linked at the individual 
level to local and national registries including the Danish 
National Patient Registry to obtain a medical history of 
the patient. This nationwide registry holds complete 
information and valid discharge diagnoses on comorbid-
ities since 1977 and in-hospital treatments, eg che-
motherapy starting from 1999.11 Antineoplastic 
procedurecodes in the Danish National Patient Registry 
were recently validated showing an overall positive pre-
dictive value of 95% (95% CI: 94.0–95.0).34 Detailed 
information about allo-HSCT can furthermore be supple-
mented using information from the Danish transplant 
centers.35 Finally, an important limitation is the lack of 
information regarding molecular alterations. These data 
are currently stored in local databases, but will likely be 
available to researchers in the near future.
The present study has several strengths. We conducted 
a comprehensive review of individual medical records at all 
the departments of hematology in Denmark during the 
entire study period, and we selected a high number of 
study variables. For validation, we used the same data 
sources as the ones used by the clinicians when reporting 
patients to the DMDSD. Our study also had some limita-
tions. We lacked a validation of the individual World Health 
Organization MDS subtypes and of cytogenetic alterations. 
The latter were however revised and reported according to 
the IPSS-R in 2020 by clinical cytogeneticists and will be 
available to researchers during 2021. The validation was 
performed by one physician only. However, we pre- 
specified the gold standards of the selected study variables 
to minimize the impact of this issue. Last, our validation 
sample comprised few patients with submitted information 
on the registration form including 5-year data, resulting in 
imprecise predictive values, which warrants careful 
interpretation.
Conclusion
In this nationwide study, characteristics of the MDS 
patients broadly resembled that of other MDS registries. 
For the majority of variables there were no missing data 
and data were generally valid with a predictive value 
exceeding 90% for most study variables. Thus, the 
DMDSD represents a valuable source for future 
research.
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